Stock Events

Stock Events

Autolus Therapeutics 

€1.6700
84
-€0.06-3.47% Monday 06:01

Statistics

Day High
1.67
Day Low
1.67
52W High
2.14
52W Low
1.07
Volume
0
Avg. Volume
143
Mkt Cap
444.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-385.58%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
64.81MRevenue
-249.9MNet Income

Analyst Ratings

$7.59Average Price Target
The highest estimate is 7.59.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6A3A.MU. It's not an investment recommendation.
NVIDIA
9
NVDA
Tesla
8
TSLA
AMD
8
AMD
Palantir Technologies
8
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap178.21B
Gilead Sciences, through its acquisition of Kite Pharma, is a leader in CAR-T therapy, making it a direct competitor in the oncology treatment market.
Novartis
NVS
Mkt Cap260.7B
Novartis is a major player in the CAR-T space with approved therapies, competing in the same advanced cancer treatment market as Autolus.
CRISPR Therapeutics
CRSP
Mkt Cap5B
CRISPR Therapeutics is involved in gene editing, a technology that can be applied to CAR-T therapy, making it a competitor in the gene therapy market.
Allogene Therapeutics
ALLO
Mkt Cap614.97M
Allogene Therapeutics focuses on allogeneic CAR-T therapies, which are off-the-shelf, directly competing with Autolus' personalized approach.
Precigen
PGEN
Mkt Cap2.45B
Precigen focuses on next-generation gene and cell therapies, including CAR-T, making it a competitor in the advanced therapeutic space.

About

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Show more...
CEO
Christian Martin Itin
Employees
752
Country
United Kingdom
ISIN
US05280R1005
WKN
000A2JNZJ

Listings

STU
DE
6A3A.STU
BOATS
BOATS
AUTL.BOATS
MU
DE
6A3A.MU
XNAS
US
AUTL

0 Comments

Share your thoughts

FAQ

What is Autolus Therapeutics stock price today?▼
The current price of 6A3A.MU is €1.67 EUR — it has decreased by -3.47% in the past 24 hours. Watch Autolus Therapeutics stock price performance more closely on the chart.
What is Autolus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Autolus Therapeutics stocks are traded under the ticker 6A3A.MU.
Is Autolus Therapeutics stock price growing?▼
6A3A.MU stock has fallen by -13.47% compared to the previous week, the month change is a -12.11% fall, over the last year Autolus Therapeutics has showed a +41.53% increase.
What is Autolus Therapeutics market cap?▼
Today Autolus Therapeutics has the market capitalization of 444.49M
What is Autolus Therapeutics revenue for the last year?▼
Autolus Therapeutics revenue for the last year amounts to 64.81M EUR.
What is Autolus Therapeutics net income for the last year?▼
6A3A.MU net income for the last year is -249.9M EUR.
How many employees does Autolus Therapeutics have?▼
As of September 15, 2026, the company has 752 employees.
In which sector is Autolus Therapeutics located?▼
Autolus Therapeutics operates in the Health & Wellness sector.
When did Autolus Therapeutics complete a stock split?▼
Autolus Therapeutics has not had any recent stock splits.
Where is Autolus Therapeutics headquartered?▼
Autolus Therapeutics is headquartered in LONDON, United Kingdom.